Protein tyrosine phosphatases as drug targets: PTP1B and beyond

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 6, 2002, Pages 637-647

  van Huijsduijnen, Rob Hooft ^a   Wälchli, Sébastien ^a   Ibberson, Mark ^a   Harrenga, Axel ^b  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^b ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

Cancer; Diabetes; Inflammation; Obesity; Osteoporosis; Protein tyrosine phosphatase (PTP)

Indexed keywords

ALENDRONIC ACID; BETA CATENIN; BISPHOSPHONIC ACID DERIVATIVE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; ERTIPROTAFIB; HYDROLASE INHIBITOR; IMATINIB; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; JANUS KINASE; LEPTIN; LYMPHOCYTE ANTIGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P130; PROTEIN P52; PROTEIN P70; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; GENE MUTATION; GENE SEQUENCE; HORMONE RESISTANCE; HUMAN; HUMAN GENOME; IMMUNE SYSTEM; KNOCKOUT MOUSE; MOUSE; MULTIGENE FAMILY; NONHUMAN; OBESITY; OSTEOPOROSIS; OVARY CANCER; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION;

CAPILLARY PERMEABILITY; CYCLIN-DEPENDENT KINASES; DIABETES MELLITUS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNE SYSTEM; INFECTION; INSULIN; LEPTIN; MULTIGENE FAMILY; NEOPLASM PROTEINS; NEOPLASMS; OBESITY; OSTEOPOROSIS; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTORS, ANTIGEN; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 0036928644     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.6.637     Document Type: Review

References (119)

1. MORINVILLE A, MAYSINGER D, SHAVER A: From Vanadis to Atropos: vanadium compounds as pharmacological tools in cell death signalling. Trends Pharmacol. Sci. (1998) 19(11):452-460.
2. HOOFT VAN HUIJSDUIJNEN R: Protein tyrosine phosphatases: counting the trees in the forest. Gene (1998) 225(1-2):1-8.
3. ANDERSEN JN, MORTENSEN OH, PETERS GH et al.: Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell. Biol. (2001) 21(21):7117-7136.
4. WISHART MJ, DIXON JE: Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. Trends Bio Chem. Sci. (1998) 23(8):301-306.
5. MAEHAMA T, TAYLOR GS, DIXON JE: PTEN and myotubularin: novel phosphoinositide phosphatases. Ann. Rev. Biochem (2001) 70:247-279.
6. KERK D, BULGRIEN J, SMITH DW, BARSAM B, VERETNIK S, GRIBSKOV M: The complement of protein phosphatase catalytic subunits encoded in the genome of Arabidopsis. Plant Physiol. (2002) 129(2):908-925.
7. HILTON DJ: Negative regulators of cytokine signal transduction. Cell. Mol. Life Sci. (1999) 55(12):1568-1577.
8. HAJ FG, VERVEER PJ, SQUIRE A, NEEL BG, BASTIAENS PI: Imaging sites of receptor dephosphorylation by PTP 1B on the surface of the endoplasmic reticulum. Science (2002) 295(5560):1708-1711.
9. ESPANEL X, WÄLCHLI S, PESCINI GOBERT R et al.: Pulling strings below the surface: hormone receptor signaling through inhibition of protein tyrosine phosphatases. Endocrine (2001) 15(1):19-28.
10. ÖSTMAN A, BÖHMER FD: Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol. (2001) 11(6):258-266.
11. GARTON AJ, FLINT AJ, TONKS NK: Identification of p130(cas) as a substrate for the cytosolic protein tyrosine phosphatase PTP-PEST. Mol. Cell. Biol. (1996) 16(11):6408-6418.
12. GARTON AJ, BURNHAM MR, BOUTON AH, TONKS NK: Association of PTP-PEST with the SH3 domain of p130cas; a novel mechanism of protein tyrosine phosphatase substrate recognition. Oncogene (1997) 15(8):877-885.
13. BUIST A, BLANCHETOT C, TERTOOLEN LG, DEN HERTOG J: Identification of p130cas as an in vivo substrate of receptor protein-tyrosine phosphatase alpha. J. Biol. Chem. (2000) 275(27):20754-20761.
14. WENG LP, WANG X, YU Q: Transmembrane tyrosine phosphatase LAR induces apoptosis by dephosphorylating and destabilizing p130Cas. Genes Cells (1999) 4(3):185-196.
15. WANG X, WENG LP, YU Q: Specific inhibition of FGF-induced MAPK activation by the receptor-like protein tyrosine phosphatase LAR. Oncogene (2000) 19(19):2346-2353.
16. LIU F, SELLS MA, CHERNOFF J: Transformation suppression by protein tyrosine phosphatase 1B requires a functional SH3 ligand. Mol. Cell. Biol. (1998) 18(1):250-259.
17. LIU F, SELLS MA, CHERNOFF J: Protein tyrosine phosphatase 1B negatively regulates integrin signaling. Curr. Biol. (1998) 8(3):173-176.
18. MANIE SN, ASTIER A, HAGHAYEGHI N et al.: Regulation of integrin-mediated p130(Cas) tyrosine phosphorylation in human B cells. A role for p59(Fyn) and SHP2. J. Biol. Chem. (1997) 272(25):15636-15641.
19. NOGUCHI T, TSUDA M, TAKEDA H et al.: Inhibition of cell growth and spreading by stomach cancer-associated protein-tyrosine phosphatase-1 (SAP-1) through dephosphorylation of p 130cas. J. Biol. Chem. (2001) 276(18):15216-15224.
20. DAVID M, CHEN HE, GOELZ S, LARNER AC, NEEL BG: Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. (1995) 15(12):7050-7058.
21. TENEV T, BOHMER SA, KAUFMANN R et al.: Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells. Eur. J. Cell. Biol. (2000) 79(4):261-271.
22. SYMES A, STAHL N, REEVES SA et al.: The protein tyrosine phosphatase SHP-2 negatively regulates ciliary neurotrophic factor induction of gene expression. Curr. Biol. (1997) 7(9):697-700.
23. TANUMA N, SHIMA H, NAKAMURA K, KIKUCHI K: Protein tyrosine phosphatase epsilon C selectively inhibits interleukin-6-and interleukin-10-induced JAK-STAT signaling. Blood (2001) 98(10):3030-3034.
24. TANUMA N, NAKAMURA K, SHIMA H, KIKUCHI K: Protein-tyrosine phosphatase PTPepsilon C inhibits Jak-STAT signaling and differentiation induced by interleukin-6 and leukemia inhibitory factor in M1 leukemia cells. J. Biol. Chem. (2000) 275(36):28216-28221.
25. BERCHTOLD S, VOLAREVIC S, MORIGGL R, MERCEP M, GRONER B: Dominant negative variants of the SHP-2 tyrosine phosphatase inhibit prolactin activation of Jak2 (janus kinase 2) and induction of Stat5 (signal transducer and activator of transcription 5)-dependent transcription. Mol. Endocrinol. (1998) 12(4):556-567.
26. YU CL, JIN YJ, BURAKOFF SJ: Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation. J. Biol. Chem. (2000) 275(1):599-604.
27. AOKI N, MATSUDA T: A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J. Biol. Chem. (2000) 275(50):39718-39726.
28. AOKI N, MATSUDA T: A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus. Mol. Endocrinol. (2002) 16(1):58-69.
29. HAQUE SJ, HARBOR P, TABRIZI M, YI T, WILLIAMS BR: Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J. Biol. Chem. (1998) 273(51):33893-33896.
30. MUSTELIN T, WILLIAMS S, TAILOR P et al.: Regulation of the p70zap tyrosine protein kinase in T cells by the CD45 phosphotyrosine phosphatase. Eur. J. Immunol. (1995) 25(4):942-946.
31. RAAB M, RUDD CE: Hematopoietic cell phosphatase (HCP) regulates p56LCK phosphorylation and ZAP-70 binding to T cell receptor zeta chain. Bioch. Biophys. Res. Comm. (1996) 222(1):50-57.
32. TIGANIS T, BENNETT AM, RAVICHANDRAN KS, TONKS NK: Epidermal growth factor receptor and the adaptor protein p52Shc are specific substrates of T-cell protein tyrosine phosphatase. Mol. Cell. Biol. (1998) 18(3):1622-1634.
33. CONG F, SPENCER S, COTE JF et al.: Cytoskeletal protein PSTPIP1 directs the PEST-type protein tyrosine phosphatase to the c-Abl kinase to mediate Abl dephosphorylation. Mol. Cell (2000) 6(6):1413-1423.
34. IRIE-SASAKI J, SASAKI T, MATSUMOTO W et al.: CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature (2001) 409(6818):349-354.
35. MYERS MP, ANDERSEN JN, CHENG A et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J. Biol. Chem. (2001) 276(51):47771-47774.
36. GOLDSTEIN BJ, BITTNER-KOWALCZYK A, WHITE MF, HARBECK M: Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J. Biol. Chem. (2000) 275(6):4283-4289.
37. ZABOLOTNY JM, KIM YB, PERONI OD et al.: Overexpression of the LAR (leukocyte antigen-related) protein-tyrosinec phosphatase in muscle causes insulin resistance. Proc. Natl. Acad. Sci. USA (2001) 98(9):5187-5192.
38. ZHENG XM, WANG Y, PALLEN CJ: Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature (1992) 359(6393):336-339.
39. DEN HERTOG J, PALS CE, PEPPELENBOSCH MP, TERTOOLEN LG, DE LAAT SW, KRUIJER W: Receptor protein tyrosine phosphatase alpha activates pp60c-src and is involved in neuronal differentiation. EMBO J. (1993) 12(10):3789-3798.
40. BHANDARI V, LIM KL, PALLEN CJ: Physical and functional interactions between receptor-like protein-tyrosine phosphatase alpha and p59fyn. J. Biol. Chem. (1998) 273(15):8691-8698.
41. HURLEY TR, HYMAN R. SEFTON BM: Differential effects of expression of the CD45 tyrosine protein phosphatase on the tyrosine phosphorylation of the lck, fyn, and c-src tyrosine protein kinases. Mol. Cell. Biol. (1993) 13(3):1651-1656.
42. CAHIRMCFARLAND ED, HURLEY TR, PINGEL JT, SEFTON BM, SHAW A, THOMAS ML: Correlation between Src family member regulation by the protein-tyrosine-phosphatase CD45 and transmembrane signaling through the T-cell receptor. Proc. Natl. Acad. Sci. USA (1993) 90(4):1402-1406.
43. FANG KS, SABE H, SAITO H, HANAFUSA H: Comparative study of three protein-tyrosine phosphatases. Chicken protein-tyrosine phosphatase lambda dephosphorylates c-Src tyrosine 527. J. Biol. Chem. (1994) 269(31):20194-20200.
44. NGUYEN TH, LIU J, LOMBROSO PJ: Striatal enriched phosphatase 61 dephosphorylates fyn at phosphotyrosine 420. J. Biol. Chem. (2002) 277(27):24274-24279.
45. MOLLER NP, MOLLER KB, LAMMERS R, KHARITONENKOV A, SURES I, ULLRICH A: Src kinase associates with a member of a distinct subfamily of protein-tyrosine phosphatases containing an ezrin-like domain. Proc. Natl. Acad. Sci. USA (1994) 91(16):7477-7481.
46. PENG ZY, CARTWRIGHT CA: Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association. Oncogene (1995) 11(10):1955-1962.
47. BJORGE JD, PANG A, FUJITA DJ: Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell fines. J. Biol. Chem. (2000) 275(52):41439-41446.
48. CHENG A, BAL GS, KENNEDY BP, TREMBLAY ML: Attenuation of adhesion-dependent signaling and cell spreading in transformed fibroblasts lacking protein tyrosine phosphatase-1B. J. Biol. Chem. (2001) 276(28):25848-25855.
49. PALMER A, ZIMMER M, ERDMANN KS et al.: EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol. Cell (2002) 9(4):725-737.
50. MENG K, RODRIGUEZ-PENA A, DIMITROV T et al.: Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptortype protein tyrosine phosphatase beta/zeta. Proc. Natl. Acad. Sci. USA (2000) 97(6):2603-2608.
51. FANTUS IG, KADOTA S, DERAGON G, FOSTER B, POSNER BI: Pervanadate [peroxide(s) of vanadate] mimics insulin action in rat adipocytes via activation of the insulin receptor tyrosine kinase. Biochemistry (1989) 28(22):8864-8871.
52. JACKSON TK, SALHANICK AI, SPARKS JD, SPARKS CE, BOLOGNINO M, AMATRUDA JM: Insulin-mimetic effects of vanadate in primary cultures of rat hepatocytes. Diabetes (1988) 37(9):1234-1240.
53. KLAMAN LD, BOSS O, PERONI OD et al.: Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. (2000) 20(15):5479-5489.
54. ELCHEBLY M, PAYETTE P, MICHALISZYN E et al.: Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science (1999) 283(5407):1544-1548.
55. MØLLER N, IVERSEN L, ANDERSEN HS, MCCORMACK JG: Protein tyrosine phosphatases (PTPs) as drug targets: inhibitors of PTP1B for the treatment of diabetes. Curr. Opin. Drug Disc. Dev. (2000) 3(5):527-540.
56. BROWER V: Fighting fat: new drugs against obesity in the pipeline. EMBO Rep. (2002) 3(7):601-602.
57. WÄLCHLI S, CURCHOD M-L, PESCINI GOBERT R, ARKINSTALL S, HOOFT VAN HUIJSDUIJNEN R: Identification of tyrosine phosphatases that dephosphorylate the insulin receptor: a brute-force approach based on 'substrate-trapping' mutants. J. Biol. Chem. (2000) 275(13):9792-9796.
58. COOK WS, UNGER RH: Protein tyrosine phosphatase 1B: a potential leptin resistance factor of obesity. Dev. Cell (2002) 2(4):385-387.
59. BYTH KF, CONROY LA, HOWLETT S et al.: CD45-null transgenic mice reveal a positive regulatory role for CD45 in early thymocyte development, in the selection of CD4+CD8+ thymocytes, and B cell maturation. J. Exp. Med. (1996) 183(4):1707-1718.
60. KISHIHARA K, PENNINGER J, WALLACE VA et al.: Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice. Cell (1993) 74(1):143-156.
61. LINCOLN AJ, WICKRAMASINGHE D, STEIN P et al.: Cdc25b phosphatase is required for resumption of meiosis during oocyte maturation. Nat. Genet. (2002) 30(4):446-449.
62. CHEN MS, HUROV J, WHITE LS, WOODFORD-THOMAS T, PIWNICAWORMS H: Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase. Mol. Cell. Biol. (2001) 21(12):3853-3861.
63. RUIVENKAMP CA, VAN WEZEL T, ZANON C et al.: Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. Nat. Genet. (2002) 31(3):295-300.
64. MINASSIAN BA, LEE JR, HERBRICK JA et al.: Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet. (1998) 20(2):171-174.
65. GANESH S, DELGADO-ESCUETA AV, SAKAMOTO T et al.: Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum. Mol. Genet. (2002) 11(11):1251-1262.
66. WHARRAM BL, GOYAL M, GILLESPIE PJ et al.: Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J. Clin. Invest. (2000) 106(10):1281-1290.
67. SCHAAPVELD RQ, SCHEPENS JT, ROBINSON GW et al.: Impaired mammary gland development and function in mice lacking LAR receptor like tyrosine phosphatase activity. Dev. Biol. (1997) 188(1):134-146.
68. REN JM, LI PM, ZHANG WR et al.: Transgenic mice deficient in the LAR protein-tyrosine phosphatase exhibit profound defects in glucose homeostasis. Diabetes (1998) 47(3):493-497.
69. GRONDA M, ARAB S, IAFRATE B, SUZUKI H, ZANKE BW: Hematopoietic protein tyrosine phosphatase suppresses extracellular stimulus-regulated kinase activation. Mol. Cell. Biol. (2001) 21(20):6851-6858.
70. DORFMAN K, CARRASCO D, GRUDA M, RYAN C, LIRA SA, BRAVO R: Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene (1996) 13(5):925-931.
71. LAPORTE J, HU LJ, KRETZ C et al.: A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat. Genet. (1996) 13(2):175-182.
72. BOLINO A, MUGLIA M, CONFORTI FL et al.: Charcot-Marie-Tooth Type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat. Genet. (2000) 25(1):17-19.
73. DI CRISTOFANO A, PESCE B, CORDON-CARDO C, PANDOLFI PP: PTEN is essential for embryonic development and tumour suppression. Nat. Genet. (1998) 19(4):348-355.
74. DAHIA PL: PTEN, a unique tumor suppressor gene. Endocr. Relat. Cancer (2000) 7(2):115-129.
75. PONNIAH S, WANG DZ, LIM KL, PALLEN CJ: Targeted disruption of the tyrosine phosphatase PTPalpha leads to constitutive downregulation of the kinases Src and Fyn. Curr. Biol. (1999) 9(10):535-538.
76. UETANI N, KATO K, OGURA H et al.: Impaired learning with enhanced hippocampal long-term potentiation in PTPδ-deficient mice. EMBO J. (2000) 19(12):2775-2785.
77. +) channels in mice lacking protein tyrosine phosphatase epsilon. EMBO J. (2000) 19(15):4036-4045.
78. SAEKI K, ZHU M, KUBOSAKI A, XIE J, LAN MS, NOTKINS AL: Targeted disruption of the protein tyrosine phosphatase-like molecule IA-2 results in alterations in glucose tolerance tests and insulin secretion. Diabetes (2002) 51(6):1842-1850.
79. SKARNES WC, MOSS JE, HURTLEY SM, BEDDINGTON RS: Capturing genes encoding membrane and secreted proteins important for mouse development. Proc. Natl. Acad. Sci. USA (1995) 92(14):6592-6596.
80. DEN HERTOG J, BLANCHETOT C, BUIST A. OVERVOORDE J, VAN DER SAR A, TERTOOLEN LG: Receptor protein-tyrosine phosphatase signalling in development. Int. J. Dev. Biol. (1999) 43(7):723-733.
81. ELCHEBLY M, WAGNER J, KENNEDY TE et al.: Neuroendocrine dysplasia in mice lacking protein tyrosine phosphatase sigma. Nat. Genet. (1999) 21(3):330-333.
82. HARROCH S, PALMERI M, ROSENBLUTH J et al.: No obvious abnormality in mice deficient in receptor protein tyrosine phosphatase β. Mol. Cell. Biol. (2000) 20(20):7706-7715.
83. TSUI HW, SIMINOVITCH KA, DE SOUZA L, TSUI FW: Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat. Genet. (1993) 4(2):124-129.
84. KOZLOWSKI M, MLINARIC-RASCAN I, FENG GS, SHEN R, PAWSON T, SIMINOVITCH KA: Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice. J. Exp. Med. (1993) 178(6):2157-2163.
85. UMEDA S, BEAMER WG, TAKAGI K et al.: Deficiency of SHP-1 protein-tyrosine phosphatase activity results in heightened osteoclast function and decreased bone density. Am. J. Pathol. (1999) 155(1):223-233.
86. SAXTON TM, CIRUNA BG, HOLMYARD D et al.: The SH2 tyrosine phosphatase SHP2 is required for mammalian limb development. Nat. Genet. (2000) 24:420-423.
87. YU DH, QU CK, HENEGARIU O. LU X, FENG GS: Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. J. Biol. Chem. (1998) 273(33):21125-21131.
88. ARRANDALE JM, GORE-WILLSE A, ROCKS S et al.: Insulin signaling in mice expressing reduced levels of Syp. J. Biol. Chem. (1996) 271(35):21353-21358.
89. YOU-TEN KE, MUISE ES, ITIE A et al.: Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J. Exp. Med. (1997) 186(5):683-693.
90. NEEL BG: Introduction: phosphatases in the immune system. Semim Immunol. (2000) 12(4):347-348.
91. ALEXANDER DR: The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. Semin. Immunol. (2000) 12(4):349-359.
92. ZHANG J, SOMANI AK, SIMINOVITCH KA: Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin. Immunol. (2000) 12(4):361-378.
93. IBARRA-SANCHEZ MJ, SIMONCIC PD, NESTEL FR, DUPLAY P, LAPP WS, TREMBLAY ML: The T-cell protein tyrosine phosphatase. Semin. Immunol. (2000) 12(4):379-386.
94. SAXENA M, MUSTELIN T: Extracellular signals and scores of phosphatases: all roads lead to MAP kinase. Semin. Immunol. (2000) 12(4):387-396.
95. KRYSTAL G: Lipid phosphatases in the immune system. Semin. Immunol. (2000) 12(4):397-403.
96. BLISKA JB, GUAN KL, DIXON JE, FALKOW S: Tyrosine phosphate hydrolysis of host proteins by an essential Yersinia virulence determinant. Proc. Natl. Acad. Sci. USA (1991) 88(4):1187-1191.
97. DEVINNEY I, STEELE-MORTIMER I, FINLAY BB: Phosphatases and kinases delivered to the host cell by bacterial pathogens. Trends Microbiol. (2000) 8(1):29-33.
98. HIGASHI H, TSUTSUMI R, MUTO S et al.: SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein. Science (2002) 295(5555):683-686.
99. MURLI S, WATSON RO, GALAN JE: Role of tyrosine kinases and the tyrosine phosphatase SptP in the interaction of Salmonella with host cells. Cell. Micrabiol. (2001) 3(12):795-810.
100. PATHAK MK, YI T: Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J. Immunol. (2001) 167(6):3391-3397.
101. JAIN RK, MUNN LL: Leaky vessels? Call Ang1! Nat. Med. (2000) 6(2):131-132.
102. FACHINGER G, DEUTSCH U, RISAU W: Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2. Oncogene(1999) 18(43):5948-5953.
103. THOMPSON LJ, JIANG J, MADAMANCHI N, RUNGE MS, PATTERSON C: PTP-ε, a tyrosine phosphatase expressed in endothelium, negatively regulates endothelial cell proliferation. Am. J. Physiol. Heart Circ. Physiol. (2001) 281(1):H396-H403.
104. MANZANO RG, MONTUENGA. LM, DAYTON M et al.: CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene (2002) 21(28):4435-4447.
105. MYERS MP, PASS I, BATTY IH et al.: The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc. Natl. Acad. Sci. USA (1998) 95(23):13513-13518.
106. DOMBRÁDI V, KRIEGLSTEIN J, KLUMPP S: Regulating the regulators. Conference on protein phosphorylation and protein phosphatases. EMBO Rep. (2002) 3(2):120-124.
107. GALAKTIONOV K, LEE AK, ECKSTEIN J et al.: CDC25 phosphatases as potential human oncogenes. Science (1995) 269(5230):1575-1577.
108. LAZO JS, NEMOTO K, PESTELL KE et al.: Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol. Pharmacol. (2002) 61(4):720-728.
109. SAHA S, BARDELLI A, BUCKHAULTS P et al.: A phosphatase associated with metastasis of colorectal cancer. Science (2001) 294(5545):1343-1346.
110. SUHR SM, PAMULA S, BAYLINK DJ, LAU KH: Antisense oligodeoxynucleotide evidence that a unique osteoclastic protein-tyrosine phosphatase is essential for osteoclastic resorption. J. Bone Miner. Res. (2001) 16(10):1795-1803.
111. SCHMIDT A, RUTLEDGE SJ, ENDO N et al.: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc. Natl. Acad. Sci. USA (1996) 93(7):3068-3073.
112. TUSCHL T: Expanding small RNA interference. Nat. Biotechnol. (2002) 20(5):446-448.
113. MIYAGISHI M, TAIRA K: U6 promoter driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat. Biotechnol. (2002) 20(5):497-500.
114. LEE NS, DOHJIMA T, BAUER G et al.: Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. (2002) 20(5):500-505.
115. PAUL CP, GOOD PD, WINER I, ENGELKE DR: Effective expression of small interfering RNA in human cells. Nat. Biotechnol (2002) 20(5):505-508.
116. SUI G, SOOHOO C, AFFAR EL B, GAY F, SHI Y, FORRESTER WC: A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA (2002) 99(8):5515-5520.
117. PADDISON PJ, CAUDY AA, BERNSTEIN E, HANNON GJ, CONKLIN DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. (2002) 16(8):948-958.
118. BLASKOVICH MA, KIM HO: Recent discovery and development of protein tyrosine phosphatase inhibitors. Expert Opin. Ther. Patents (2002) 12(6):871-905.
119. ZINKER BA, RONDINONE CM, TREVILLYAN JM et al.: PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc. Natl. Acad. Sci. USA (2002) 99(17):11357-11362.